Hims and Hers Health Offers Affordable Wegovy Alternative Amid Pricing Pressure

Hims and Hers Health introduces a cost-effective version of Novo Nordisk's Wegovy weight-loss pill, starting at $49 per month. This move, sparking an 8.6% drop in Novo's shares, comes amid heightened pricing pressure and disputes over compounded drug markets, influencing both consumer choices and industry competition.

In a strategic move to capture the weight-loss market, Hims and Hers Health revealed its plan to offer a compounded version of Novo Nordisk's Wegovy pill at an introductory cost of $49 a month, potentially disrupting the market dynamics.

The announcement led to a significant dip in Novo Nordisk's shares, dropping 8.6% by early morning trading, as the pharmaceutical giant grapples with unprecedented pricing pressure and competition from Eli Lilly.

While Novo Nordisk criticizes the marketing of unregulated compounded drugs, Hims CEO Andrew Dudum advocates for consumer choice and cost savings. Compounding practices flourish, with Hims expanding its Ohio facility to cater to increased demand at competitive prices.

(With inputs from agencies.)